Artiva halts lead cell therapy, cuts 94 percent of staff

Artiva Biotherapeutics is halting all further development of AlloNK, its allogeneic natural killer cell therapy, cutting about 94 percent of its workforce and starting a process to explore strategic alternatives, the company said in an SEC filing on Tuesday.

Why it matters: The San Diego company is effectively winding down its operating business with about $319 million of cash and investments on hand, which makes the strategic alternatives process, rather than any clinical programme, the remaining question for shareholders.

Data as of Artiva Biotherapeutics Form 8-K filed October 27, 2026 (accession 0001193125-26-432806), read in full in this run from the filing text cached by the SEC filings lane. The board decision was taken on October 22, 2026. The cash figure is preliminary and unaudited, on the company's own statement. Developing item.

Artiva Biotherapeutics is halting all further development of AlloNK (AB-101), its non-genetically modified, allogeneic natural killer cell therapy candidate, and has begun a process to explore strategic alternatives, the company said in a Form 8-K filed on Tuesday. The board approved the discontinuation on October 22, and the wind down includes a reduction of the workforce by about 94 percent of the current employee base, which the company expects to complete in the first quarter of 2027.

The company reported preliminary cash, cash equivalents and investments of about $319.1 million as of September 30, 2026, and said it could not yet reasonably estimate the total costs and charges of the wind down, which will cover clinical trial termination, leases and the workforce reduction, with most of the costs expected in the fourth quarter of 2026. Complete quarterly results will follow in its Form 10-Q for the quarter ended September 30.

Artiva halts lead cell therapy, cuts 94 percent of staff

Sources